39.76
price up icon3.54%   1.36
pre-market  Vorhandelsmarkt:  39.10   -0.66   -1.66%
loading
Schlusskurs vom Vortag:
$38.40
Offen:
$38.9
24-Stunden-Volumen:
9.36M
Relative Volume:
0.34
Marktkapitalisierung:
$8.72B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
57.62
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
+14.55%
1M Leistung:
-15.62%
6M Leistung:
-25.46%
1J Leistung:
+31.05%
1-Tages-Spanne:
Value
$38.52
$39.87
1-Wochen-Bereich:
Value
$35.01
$39.87
52-Wochen-Spanne:
Value
$23.97
$72.98

Hims Hers Health Inc Stock (HIMS) Company Profile

Name
Firmenname
Hims Hers Health Inc
Name
Telefon
415-851-0195
Name
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Name
Mitarbeiter
1,637
Name
Twitter
Name
Nächster Verdiensttermin
2025-02-24
Name
Neueste SEC-Einreichungen
Name
HIMS's Discussions on Twitter

Vergleichen Sie HIMS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
HIMS
Hims Hers Health Inc
39.76 8.74B 1.78B 164.40M 236.51M 0.69
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
128.18 56.27B 9.40B 2.65B 2.24B 5.935
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.42 45.87B 29.63B 260.53M 5.51B 0.0788
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.78 43.46B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
26.89 30.20B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
486.00 21.03B 3.08B 1.24B 1.07B 25.61

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-21 Eingeleitet KeyBanc Capital Markets Sector Weight
2025-06-23 Herabstufung Needham Buy → Hold
2025-06-04 Bestätigt Needham Buy
2025-04-29 Herabstufung TD Cowen Buy → Hold
2025-02-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2025-01-10 Herabstufung Citigroup Neutral → Sell
2025-01-07 Eingeleitet BTIG Research Buy
2024-12-17 Eingeleitet Morgan Stanley Overweight
2024-11-14 Herabstufung BofA Securities Buy → Underperform
2024-08-22 Eingeleitet Needham Buy
2024-08-09 Herabstufung Imperial Capital Outperform → In-line
2024-05-22 Herabstufung Citigroup Buy → Neutral
2024-04-16 Herabstufung Jefferies Buy → Hold
2024-04-10 Eingeleitet Canaccord Genuity Buy
2024-02-28 Hochstufung Imperial Capital In-line → Outperform
2024-02-26 Eingeleitet Leerink Partners Market Perform
2023-12-07 Eingeleitet Imperial Capital In-line
2023-07-28 Eingeleitet TD Cowen Outperform
2023-04-11 Eingeleitet Robert W. Baird Neutral
2023-02-09 Hochstufung Jefferies Hold → Buy
2022-11-08 Hochstufung BofA Securities Neutral → Buy
2022-11-08 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-10-17 Herabstufung Piper Sandler Overweight → Neutral
2022-09-07 Eingeleitet Truist Hold
2022-07-15 Eingeleitet SVB Leerink Underperform
2022-04-14 Eingeleitet Guggenheim Buy
2022-04-01 Fortgesetzt Credit Suisse Outperform
2022-03-10 Eingeleitet Deutsche Bank Hold
2021-12-02 Eingeleitet Jefferies Hold
2021-11-11 Hochstufung Piper Sandler Neutral → Overweight
2021-07-06 Eingeleitet BofA Securities Neutral
2021-05-20 Hochstufung Credit Suisse Neutral → Outperform
2021-04-21 Eingeleitet Truist Hold
2021-03-09 Eingeleitet Credit Suisse Neutral
2021-03-02 Hochstufung Citigroup Neutral → Buy
2021-02-17 Eingeleitet Citigroup Neutral
2021-02-12 Eingeleitet Piper Sandler Neutral
2021-02-08 Eingeleitet Tigress Financial Buy
Alle ansehen

Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten

pulisher
03:56 AM

Hims & Hers Health (NYSE:HIMS) Shares Flat Amid Sector Overview - Kalkine Media

03:56 AM
pulisher
Nov 30, 2025

Hims & Hers Health, Inc. (HIMS) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - The National Law Review

Nov 30, 2025
pulisher
Nov 28, 2025

Liquidity Mapping Around (HIMS) Price Events - news.stocktradersdaily.com

Nov 28, 2025
pulisher
Nov 28, 2025

HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside? - Finviz

Nov 28, 2025
pulisher
Nov 26, 2025

Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Market Challenges - Quiver Quantitative

Nov 26, 2025
pulisher
Nov 26, 2025

Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip? - The Globe and Mail

Nov 26, 2025
pulisher
Nov 26, 2025

Why Is Hims & Hers Stock Falling, and Should Investors Buy the Dip? - The Motley Fool

Nov 26, 2025
pulisher
Nov 25, 2025

Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus

Nov 25, 2025
pulisher
Nov 25, 2025

[Form 4] Hims & Hers Health, Inc. Insider Trading Activity - Stock Titan

Nov 25, 2025
pulisher
Nov 25, 2025

Why Hims & Hers moved into lab testing - Healthcare Brew

Nov 25, 2025
pulisher
Nov 25, 2025

From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform - Seeking Alpha

Nov 25, 2025
pulisher
Nov 25, 2025

Hims & Hers Expands Care Scope as Digital Health Platforms Evolve - Yahoo Finance

Nov 25, 2025
pulisher
Nov 25, 2025

Hims & Hers Health (HIMS) Launches $250 Million Buyback Amid Stock Slide - Somos Hermanos -

Nov 25, 2025
pulisher
Nov 24, 2025

Assessing Hims & Hers Health After Latest Partnerships and a 50% Year-to-Date Price Surge - Yahoo Finance

Nov 24, 2025
pulisher
Nov 24, 2025

Hims, Block, and NRG Just Launched Huge Stock Buybacks - Finviz

Nov 24, 2025
pulisher
Nov 24, 2025

Alignment Healthcare, Hims & Hers Health, Surgery Partners, Guardant Health, and Pediatrix Medical Group Stocks Trade Up, What You Need To Know - Finviz

Nov 24, 2025
pulisher
Nov 24, 2025

Hims & Hers: The Growth Story Is Outside GLP-1s - Seeking Alpha

Nov 24, 2025
pulisher
Nov 24, 2025

1 Small-Cap Stock with Exciting Potential and 2 We Avoid - Finviz

Nov 24, 2025
pulisher
Nov 22, 2025

Hims & Hers Health (NYSE:HIMS) Could Easily Take On More Debt - 富途牛牛

Nov 22, 2025
pulisher
Nov 21, 2025

Hims & Hers health authorizes $250 million share repurchase program - MSN

Nov 21, 2025
pulisher
Nov 21, 2025

How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge - Bloomberg.com

Nov 21, 2025
pulisher
Nov 21, 2025

Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model - Nasdaq

Nov 21, 2025
pulisher
Nov 21, 2025

Hims & Hers Health Options Trading: A Deep Dive into Market Sentiment - Benzinga

Nov 21, 2025
pulisher
Nov 20, 2025

OMCL or HIMS: Which Is the Better Value Stock Right Now? - sharewise.com

Nov 20, 2025
pulisher
Nov 20, 2025

Hims & Hers Health: A Notable Shift Toward Core - Smartkarma

Nov 20, 2025
pulisher
Nov 20, 2025

Hims & Hers Health Announces New Share Buyback Program - MSN

Nov 20, 2025
pulisher
Nov 19, 2025

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

Hims & Hers Health Insider Sold Shares Worth $853,490, According to a Recent SEC Filing - MarketScreener

Nov 19, 2025
pulisher
Nov 19, 2025

Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Competitive Challenges - Quiver Quantitative

Nov 19, 2025
pulisher
Nov 19, 2025

Hers Health Inc. stock surprise with earnings upside2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Analysts Have Conflicting Sentiments on These Healthcare Companies: NRX Pharmaceuticals (NRXP), LifeMD (LFMD) and Hims & Hers Health (HIMS) - The Globe and Mail

Nov 19, 2025
pulisher
Nov 18, 2025

Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell? - Finviz

Nov 18, 2025
pulisher
Nov 18, 2025

Parents Sue Hims After Washington State Student’s Suicide - USA Herald

Nov 18, 2025
pulisher
Nov 18, 2025

Commit To Purchase Hims & Hers Health At $20, Earn 27.2% Using Options - Nasdaq

Nov 18, 2025
pulisher
Nov 18, 2025

Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance

Nov 18, 2025
pulisher
Nov 18, 2025

The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 29% - simplywall.st

Nov 18, 2025
pulisher
Nov 17, 2025

Telehealth Co. Hims Sued Over College Student's Suicide - Law360

Nov 17, 2025
pulisher
Nov 17, 2025

Key facts: Hims & Hers shares fall 4.9%; Deb Autor appointed Chief Policy Officer - TradingView

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers Stock Falls Amid Weight-Loss Drug Price CompetitionNews and Statistics - IndexBox

Nov 17, 2025
pulisher
Nov 17, 2025

Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today - Finviz

Nov 17, 2025
pulisher
Nov 17, 2025

What's Going On With Hims & Hers Health Shares Monday? - Benzinga

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers Health board approves $250 million share repurchase program - Investing.com Nigeria

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers Health stock rises after announcing $250 million buyback program - MSN

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers names ex-FDA official Deb Autor as first policy chief - Reuters

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers Health, Inc. Appoints Deb Autor as the First Chief Policy Officer - MarketScreener

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers Announces New $250 Million Share Repurchase Program – Retail Sees A Steady Trading Range For The Stock - Stocktwits

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% - MSN

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE) - Seeking Alpha

Nov 17, 2025
pulisher
Nov 17, 2025

Hims & Hers announces $250 million share repurchase program - Investing.com India

Nov 17, 2025

Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.27
price down icon 0.17%
drug_manufacturers_specialty_generic RDY
$14.05
price up icon 0.43%
$10.69
price up icon 0.47%
$152.16
price up icon 0.38%
$486.00
price down icon 0.50%
Kapitalisierung:     |  Volumen (24h):